相关实验视频
Updated: Jun 10, 2025

09:12
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
Published on: July 29, 2018
8.1K
新兴的RNAi疗法治疗高血压
Pawan Daga1, Gurnoor Singh2, Tushar Menon2
1Department of Internal Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Molecular diagnosis & therapy
|October 14, 2024
概括
核糖核酸干扰 (RNAi) 为治疗高血压 (HTN) 提供了一种新的方法. 这种基因沉默技术显示了长期血压控制的前景,剂量不频繁,副作用最小.
科学领域:
- 生物技术是生物技术.
- 遗传学 是一个遗传学.
- 心血管医学 心血管医学
背景情况:
- 高血压 (HTN) 影响全球超过13亿人,构成主要的心血管风险.
- 低于最佳的血压 (BP) 控制是由衰老,肥胖,饮食不良和坚持问题的驱动.
- 新的治疗策略对于有效的长期高血压管理至关重要.
研究的目的:
- 系统地审查核酸干扰 (RNAi) 在高血压管理中的作用.
- 评估RNAi的机制,临床效用和抗高血压作用的安全性.
- 突出早期试验数据和与RNAi疗法相关的挑战.
主要方法:
- 对同行评审文章的系统文献综述.
- 在PubMed,EMBASE和Scopus数据库中进行的搜索.
- 专注于研究高血压的RNAi,包括机制,疗效和安全性.
主要成果:
- RNAi技术利用自然基因沉默来获得潜在的治疗益处.
- 早期试验表明有希望,但目标特异性和交付等挑战存在.
- RNAi显示出长期作用和不频繁剂量的潜力.
结论:
- RNAi疗法在治疗高血压方面具有显著的潜在作用.
- 独特的益处包括长时间的作用和不频繁的剂量.
- RNAi疗法显示出良好的安全性,缺乏主要的副作用.
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
siRNA - Small Interfering RNAs
16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
Antihypertensive Drugs: Direct Renin Inhibitors
505
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
505
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Antihypertensive Drugs: Angiotensin II Receptor Blockers
595
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
595

